Beyond Medical Technologies Announces Filing of Application for Management Cease Trade Order
Beyond Medical Technologies (CSE: DOCT, OTC: DOCKF) has announced it will likely miss the April 30, 2025 deadline for filing its annual financial statements and related documents for the fiscal year ended December 31, 2024. The company has applied for a Management Cease Trade Order (MCTO) with the British Columbia Securities Commission due to delays caused by a recent management team transition.
The company expects to complete the Annual Filings by June 30, 2025. During the MCTO period, public trading of shares will continue, but company executives and certain insiders will be restricted from trading. Beyond Medical will issue bi-weekly status updates and comply with alternative information guidelines under National Policy 12-203.
Beyond Medical Technologies (CSE: DOCT, OTC: DOCKF) ha annunciato che probabilmente non riuscirà a rispettare la scadenza del 30 aprile 2025 per la presentazione del bilancio annuale e dei documenti correlati relativi all’esercizio chiuso al 31 dicembre 2024. La società ha richiesto un Management Cease Trade Order (MCTO) alla British Columbia Securities Commission a causa di ritardi dovuti a un recente cambio del team di gestione.
La società prevede di completare le dichiarazioni annuali entro il 30 giugno 2025. Durante il periodo del MCTO, la negoziazione pubblica delle azioni continuerà, ma i dirigenti della società e alcuni insider saranno limitati nelle operazioni di trading. Beyond Medical fornirà aggiornamenti sullo stato ogni due settimane e rispetterà le linee guida alternative sull’informazione previste dalla National Policy 12-203.
Beyond Medical Technologies (CSE: DOCT, OTC: DOCKF) ha anunciado que probablemente no cumplirá con la fecha límite del 30 de abril de 2025 para presentar sus estados financieros anuales y documentos relacionados correspondientes al ejercicio fiscal finalizado el 31 de diciembre de 2024. La empresa ha solicitado una Orden de Suspensión de Comercio para la Dirección (MCTO) ante la Comisión de Valores de Columbia Británica debido a retrasos causados por una reciente transición en el equipo directivo.
La compañía espera completar las presentaciones anuales antes del 30 de junio de 2025. Durante el período del MCTO, la negociación pública de las acciones continuará, pero los ejecutivos y ciertos insiders tendrán restricciones para operar. Beyond Medical emitirá actualizaciones quincenales sobre el estado y cumplirá con las directrices alternativas de información bajo la Política Nacional 12-203.
Beyond Medical Technologies (CSE: DOCT, OTC: DOCKF)는 2024년 12월 31일 종료된 회계연도에 대한 연례 재무제표 및 관련 서류 제출 마감일인 2025년 4월 30일을 지키지 못할 가능성이 있다고 발표했습니다. 회사는 최근 경영진 교체로 인한 지연으로 인해 브리티시컬럼비아 증권위원회에 경영진 거래중지 명령(MCTO)을 신청했습니다.
회사는 2025년 6월 30일까지 연례 제출을 완료할 것으로 예상합니다. MCTO 기간 동안 주식의 공개 거래는 계속되지만, 회사 경영진과 일부 내부자는 거래가 제한됩니다. Beyond Medical은 2주마다 진행 상황을 업데이트하고 국가 정책 12-203에 따른 대체 정보 지침을 준수할 것입니다.
Beyond Medical Technologies (CSE : DOCT, OTC : DOCKF) a annoncé qu’elle manquerait probablement la date limite du 30 avril 2025 pour le dépôt de ses états financiers annuels et des documents connexes pour l’exercice clos le 31 décembre 2024. La société a demandé une Management Cease Trade Order (MCTO) auprès de la Commission des valeurs mobilières de la Colombie-Britannique en raison de retards causés par une récente transition de l’équipe de direction.
La société prévoit de finaliser les dépôts annuels d’ici le 30 juin 2025. Pendant la période du MCTO, la négociation publique des actions se poursuivra, mais les dirigeants et certains initiés seront limités dans leurs transactions. Beyond Medical publiera des mises à jour bihebdomadaires sur l’état d’avancement et respectera les directives alternatives d’information selon la politique nationale 12-203.
Beyond Medical Technologies (CSE: DOCT, OTC: DOCKF) hat angekündigt, dass es voraussichtlich die Frist am 30. April 2025 für die Einreichung der Jahresabschlüsse und zugehörigen Unterlagen für das am 31. Dezember 2024 endende Geschäftsjahr nicht einhalten wird. Das Unternehmen hat bei der British Columbia Securities Commission eine Management Cease Trade Order (MCTO) beantragt, bedingt durch Verzögerungen infolge eines kürzlichen Wechsels im Managementteam.
Das Unternehmen erwartet, die Jahresunterlagen bis zum 30. Juni 2025 fertigzustellen. Während der MCTO-Periode wird der öffentliche Handel mit Aktien fortgesetzt, jedoch werden Führungskräfte und bestimmte Insider im Handel eingeschränkt. Beyond Medical wird alle zwei Wochen Statusupdates veröffentlichen und die alternativen Informationsrichtlinien gemäß der National Policy 12-203 einhalten.
- Public trading of shares continues unaffected
- Company not subject to insolvency proceedings
- Delayed filing of 2024 annual financial statements and related documents
- Management team transition causing operational delays
- Trading restrictions imposed on company insiders and executives
Vancouver, British Columbia--(Newsfile Corp. - April 16, 2025) - Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM) (OTC Pink: DOCKF) ("Beyond Medical" or the "Company") announced today that it will likely miss its filing deadline of April 30, 2025 to file audited annual financial statements and accompanying management's discussion and analysis and related CEO and CFO certificates for the financial year ended December 31, 2024 (collectively, the "Annual Filings"), as required under applicable Canadian securities laws.
In connection with the Company's inability to file the Annual Filings on time, the Company has applied for a Management Cease Trade Order ("MCTO") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203") and is waiting for the British Columbia Securities Commission approval.
The Company is applying for a MCTO as a result of delays caused by the recent transition to a new management team.
The Company expects to file the Annual Filings as soon as they are available and by no later than June 30, 2025. The Company will issue a news release once the Annual Filings have been filed. Until the Company files the Annual Filings, it will comply with the alternative information guidelines set out in NP 12-203. The guidelines, among other things, require the Company to issue bi-weekly default status reports, in the form of news releases, for so long as the Annual Filings have not been filed.
During the MCTO, the general investing public will continue to be able to trade in the Company's common shares listed on the Canadian Securities Exchange. However, the Company's Chief Executive Officer, Chief Financial Officer and such other directors, officers and persons as determined by the applicable regulatory authorities will not be able to trade in the Company's common shares, nor will the Company be able to, directly or indirectly, issue securities to or acquire securities from an insider or employee of the Company except in accordance with legally binding obligations to do so existing as of April 30, 2025, being the date of the Company's anticipated continuous disclosure default.
The Company is not subject to any insolvency proceedings. If the Company provides any information to any of its creditors during the period in which it is in default of filing the Annual Filings, the Company
About Beyond Medical Technologies Inc.
Beyond Medical Technologies Inc. is a healthcare technology company integrating blockchain infrastructure to enhance patient outcomes and operational efficiency across the medical ecosystem.
On behalf of the Board of Directors
Daniel Liu, Chief Executive Officer
Email: danzliu94@gmail.com
https://beyond-md.ca/
Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the accuracy or adequacy of this release.
Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "expects", "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions with respect to, among other things, management expectations that it will miss the filing deadline for the Annual Filings and the ability of the Company to file the Annual Filings within the time period described herein.
These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the Company being unable file the Annual Filings in the proposed timeframe; recent market volatility; and the state of the financial markets for the Company's securities.
In making the forward looking statements in this news release, the Company has applied several material assumptions, including without limitation, that: the Company will be able to file the Annual Filings in the proposed time frame.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/248858
FAQ
Why did Beyond Medical Technologies (DOCKF) request a Management Cease Trade Order in April 2025?
Can investors trade Beyond Medical (DOCKF) shares during the Management Cease Trade Order?
When will Beyond Medical Technologies (DOCKF) file its 2024 annual financial statements?
What are the reporting requirements for Beyond Medical during the MCTO period?
